Neumora Therapeutics Inc Stock Price, News & Analysis

Neumora Therapeutics (Nasdaq: NMRA), a clinical-stage biopharmaceutical company focused on brain disease treatments, has announced its upcoming presentation at the Leerink Global Healthcare Conference. The presentation is scheduled for Tuesday, March 11, 2025, at 10:00 a.m. ET in Miami, FL.

The company, which maintains a pipeline of seven clinical and pre-clinical brain disease programs, will make the presentation available via live webcast on their website's Events and Presentations section at www.neumoratx.com. The recording will remain accessible for up to 30 days following the event.

Neumora Therapeutics (NMRA) has reported its Q4 and full year 2024 financial results, highlighting key developments in its neuroscience pipeline. The company ended 2024 with $307.6 million in cash and equivalents, expected to fund operations into mid-2026.

Following analysis of KOASTAL-1 results, Neumora has optimized its KOASTAL-2 and -3 studies for major depressive disorder treatment, with topline data expected in Q1 and Q2 2026 respectively. The company has paused and plans to resume these studies in March 2025 with enhanced site selection and medical monitoring.

Key financial metrics for 2024 include R&D expenses of $200.9 million (up from $142.7 million in 2023) and G&A expenses of $62.5 million (up from $45.5 million). The company reported a net loss of $243.8 million for the full year 2024.

Neumora Therapeutics (NASDAQ: NMRA) announced significant leadership changes effective February 14, 2025. Paul L. Berns, co-founder and executive chair, will become CEO and chairman of the Board, replacing Henry Gosebruch. Joshua Pinto, Ph.D., will serve as president, Bill Aurora, Pharm.D., as chief operating and development officer, and Michael Milligan as chief financial officer.

The clinical-stage biopharmaceutical company has seven clinical and pre-clinical brain disease programs in its pipeline, with clinical data readouts expected from all three clinical-stage programs in 2025. A key highlight is the ongoing Phase 3 program with navacaprant in depression. The company focuses on developing novel treatments for brain diseases with therapeutically relevant targets and best-in-class pharmacology.

Neumora will host a conference call on March 3, 2025, to report Q4 and full-year 2024 financial results and provide a business update.

Neumora Therapeutics (NASDAQ: NMRA) announced disappointing results from its Phase 3 KOASTAL-1 Study of navacaprant for major depressive disorder (MDD). The study failed to meet its primary endpoint, showing no statistically significant improvement in depressive symptoms compared to placebo as measured by MADRS total score at Week 6.

Key findings from the 383-patient study include:

• No significant difference between navacaprant and placebo in the overall population
• An efficacy signal observed in female participants (-14.0 vs -11.4 placebo)
• The drug was generally well-tolerated with no serious adverse events

The company reported $342 million cash balance as of Q3, providing runway into mid-2026. Two additional Phase 3 studies (KOASTAL-2 and KOASTAL-3) and a long-term study (KOASTAL-LT) are ongoing.

Neumora Therapeutics (NMRA) reported Q3 2024 financial results with a net loss of $72.5 million, compared to $53.0 million in Q3 2023. R&D expenses increased to $60.6 million from $41.6 million year-over-year. The company maintains a strong financial position with $341.3 million in cash and equivalents, expected to fund operations into mid-2026.

Key pipeline updates include expected Phase 3 KOASTAL-1 study data for navacaprant in major depressive disorder (MDD) by end of 2024, with KOASTAL-2 and KOASTAL-3 results anticipated in H1 2025. Additional studies include Phase 2 trials for bipolar depression and Phase 1b study of NMRA-511 for Alzheimer's disease agitation, both with data expected in H2 2025.

Neumora Therapeutics (Nasdaq: NMRA), a clinical-stage biopharmaceutical company focused on brain disease treatments, has announced its participation in two major healthcare conferences this November. The company will present at Guggenheim's Inaugural Healthcare Innovation Conference on November 13 at 3:00 p.m. ET in Boston, and at the Stifel 2024 Healthcare Conference on November 18 at 10:20 a.m. ET in New York. Both presentations will feature management fireside chats and will be available via live webcast on the company's website, with recordings archived for up to 30 days.

Neumora Therapeutics (Nasdaq: NMRA), a clinical-stage biopharmaceutical company developing seven clinical and pre-clinical brain disease programs, has scheduled its third quarter 2024 financial results conference call and webcast for Tuesday, November 12, 2024, at 8:00 a.m. ET. The event will include a business update and will be available on the company's website, with a replay archived for up to 30 days. Participants are encouraged to register at least 10 minutes before the call.

Neumora Therapeutics (Nasdaq: NMRA) announced a roundtable discussion on the neuropsychiatric treatment landscape and the role of kappa opioid receptor antagonists (KORAs) in neuropsychiatry. The event, featuring leading experts, will take place on September 12, 2024, at 8:00 a.m. ET.

The discussion will focus on the potential of navacaprant, Neumora's KORA candidate, in treating neuropsychiatric disorders. The company is currently conducting a Phase 3 KOASTAL program for navacaprant in major depressive disorder (MDD) and a Phase 2 study in bipolar depression. Neumora expects to report topline data from the KOASTAL-1 Phase 3 study in Q4 2024.

The event will cover topics including Neumora's mission and pipeline, the role of kappa opioid receptors in MDD, navacaprant's Phase 2 data, and potential indications beyond MDD and bipolar depression.

Neumora Therapeutics (NMRA) reported Q2 2024 financial results and provided a business update. Key highlights include:

1. Phase 3 KOASTAL-1 study data for navacaprant in major depressive disorder (MDD) expected in Q4 2024.

2. Ongoing clinical studies in MDD, bipolar depression, and Alzheimer's disease agitation.

3. Strong financial position with $371.6 million in cash, cash equivalents, and marketable securities, expected to support operations into 2026.

4. Q2 2024 R&D expenses increased to $48.6 million from $32.8 million in Q2 2023.

5. Net loss for Q2 2024 was $58.7 million, compared to $38.5 million in Q2 2023.

6. Narrowed guidance to submit an IND for an additional M4 compound in H1 2025.